IONS Ionis Pharmaceuticals Inc.

51.46
+2.95  (+6%)
Previous Close 48.51
Open 49.28
Price To Book 4.87
Market Cap 7,164,250,908
Shares 139,219,800
Volume 965,111
Short Ratio
Av. Daily Volume 1,041,450
Stock charts supplied by TradingView

NewsSee all news

  1. Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

    DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)Well-established safety profile and proven efficacy of SPINRAZA in a

  2. Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO

    BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  3. Akcea Therapeutics Canada celebrates official launch of first-of-its-kind research grant program

    Young Investigator Grant Program Call for Proposals issued to Canadian researchers OTTAWA, March 13, 2020 /CNW/ - Akcea Therapeutics Canada, a subsidiary of Akcea Therapeutics Inc. (NASDAQ:AKCA), congratulates

  4. Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company's leadership team

    BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as

  5. Akcea Supports Rare Disease Day 2020 and Global Efforts to "Reframe Rare"

    BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company's support for Rare Disease Day 2020 and the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2 data met primary and secondary endpoints - January 22, 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 3 trial has been initiated - noted February 25, 2020.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2b data likely due 2020.
IONIS-FXIRx
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 3 data due 2021.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to be initiated early 2019.
IONIS-FB-LRx
Geographic Atrophy (GA)
Phase 1b/2 data likely due 2020.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 trial initiation announced November 25, 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis
Phase 2 data due 2020.
IONIS-GHR-LRx
Acromegaly
Phase 2/3 initiation announced September 18, 2019.
SPINRAZA - DEVOTE
Spinal muscular atrophy (SMA)
Phase 3 trial initiation announced January 10, 2020.
AKCEA-TTR-LRx - CARDIO-TTRansform
ATTR cardiomyopathy
Phase 2 data due 2020.
IONIS-PKK-LRx
Hereditary Angioedema
Phase 2 data due 2020.
IONIS-ENaC-2.5Rx
Healthy volunteers
Phase 2/3 commencement of dosing announced April 2, 2020.
SPINRAZA (nusinersen) - high dose
Spinal muscular atrophy (SMA)

Latest News

  1. Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study

    DEVOTE will evaluate the safety and potential for even greater efficacy of a higher dose of SPINRAZA in the treatment of spinal muscular atrophy (SMA)Well-established safety profile and proven efficacy of SPINRAZA in a

  2. Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO

    BOSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  3. Akcea Therapeutics Canada celebrates official launch of first-of-its-kind research grant program

    Young Investigator Grant Program Call for Proposals issued to Canadian researchers OTTAWA, March 13, 2020 /CNW/ - Akcea Therapeutics Canada, a subsidiary of Akcea Therapeutics Inc. (NASDAQ:AKCA), congratulates

  4. Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company's leadership team

    BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as

  5. Akcea Supports Rare Disease Day 2020 and Global Efforts to "Reframe Rare"

    BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company's support for Rare Disease Day 2020 and the

  6. Ionis Pharmaceuticals to present at upcoming investor conferences

    CARLSBAD, Calif., Feb. 27, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor

  7. Antisense Therapeutics Announces Appointment of US-based Consultant Medical Director

    Clinician with deep experience in DMD drug development (ex-Sarepta Therapeutics Director) On the ground presence in the US to accelerate development activities Initial focus on engagement with Key Opinion Leaders

  8. Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference

    BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with

  9. Ionis provides fourth quarter and full year 2019 financial results

    CARLSBAD, Calif., Feb. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today reported its financial results for the fourth quarter and full year 2019 and recent business highlights.

  10. Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019

    Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million Achieved the 2-2-2 plan: launched two products, initiated two phase 3 programs and

  11. Ionis Pharmaceuticals to hold 2019 financial results webcast

    CARLSBAD, Calif., Feb. 19, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, February 26th at 11:30 a.m. Eastern Time to discuss its 2019

  12. Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast

    BOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 25 at

  13. Ionis treatment for Alexander disease granted orphan drug status from EMA

    CARLSBAD, Calif., Feb. 11, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that the European Medicines Agency (EMA) has granted orphan drug

  14. Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx

    Favorable safety and tolerability were observed Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 BOSTON and CARLSBAD,

  15. Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

    BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced

  16. Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

    BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced

  17. Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer

    CARLSBAD, Calif., Jan. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, today announced the appointment of Onaiza Cadoret-Manier as chief corporate development

  18. Ionis' neurological franchise marks year of achievement

    CARLSBAD, Calif., Jan. 7, 2020 /PRNewswire/ -- The neurological franchise of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, continued to shape the scientific and therapeutic landscape

  19. Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference

    CARLSBAD, Calif., Jan. 6, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a

  20. New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

    Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway

  21. Ionis licenses investigational Alzheimer's therapy

    CARLSBAD, Calif., Dec. 19, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that Biogen, a collaboration partner for neurological diseases, has

  22. Akcea Retains Rights to AKCEA-APOCIII-LRx

    BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  23. Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research

    CARLSBAD, Calif., Dec. 18, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, today announced the appointments of C. Frank Bennett, Ph.D., as chief scientific

  24. Positive results reaffirm plans to advance ATL1102 for DMD to Phase IIb trial

    MELBOURNE, Australia, Dec. 16, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that the data from all nine participants having completed their 24 weeks of dosing

  25. Akcea Therapeutics Announces New Appointments to its Board of Directors

    BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall, J.D., as chair of the

  26. Ionis Pharmaceuticals announces private placement of $507.5 million principal amount of 0.125% convertible senior notes due 2024

    CARLSBAD, Calif., Dec. 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ("Ionis") announced today that it has entered into privately negotiated exchange and/or subscription agreements, with

  27. Akcea Announces Appointment of New Chief Operating Officer

    BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating

  28. Ionis Pharmaceuticals to hold technology webcast

    CARLSBAD, Calif., Dec. 2, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Friday, December 13th at 11:00 a.m. Eastern Time to take a deep dive into

  29. Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

    BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  30. Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  31. Antisense Therapeutics Announces Additional preliminary data from the ATL1102 Phase II DMD trial presented at the 2019 Action Duchenne International Conference

    MELBOURNE, Australia, Nov. 18, 2019 /PRNewswire/ -- Antisense Therapeutics (OTC:ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have completed their 24 weeks of dosing in

  32. Akcea Therapeutics to Present at Upcoming Investor Conferences

    BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with

  33. Ionis Pharmaceuticals to present at upcoming investor conferences

    CARLSBAD, Calif., Nov. 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor

  34. Ionis provides third quarter financial results and improved 2019 guidance

    CARLSBAD, Calif., Nov. 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today reported its financial results for the third quarter and year-to-date 2019 and recent business highlights.

  35. Akcea Reports Financial Results and Highlights for Third Quarter 2019

    Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-LRx Conference Call

  36. Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day

    BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today recognizes Familial Chylomicronemia Syndrome (FCS)

  37. Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences

    CARLSBAD, Calif., Oct. 23, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that Ionis' Chairman and Chief Executive Officer, Stanley T. Crooke,

  38. Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast

    CARLSBAD, Calif., Oct. 22, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third

  39. Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting

    CARLSBAD, Calif., Oct. 10, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that its scientists will present data highlighting advances in the

  40. Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

    CARLSBAD, Calif., Oct. 9, 2019 /PRNewswire/ -- IONIS-FXI-LRx, Ionis' first-in-class FXI anti-thromboticmedicine, to potentially treat millions of patients globally Ionis Pharmaceuticals,

  41. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  42. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  43. Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

    Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilationMotor milestones achieved included 100 percent of participants sitting without support and 88 percent

  44. Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year

    CARLSBAD, Calif., Sept. 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade

  45. Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

    DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefitsLong-term data from the SHINE

  46. Positive preliminary results from ATL1102 for DMD Phase II trial

    MELBOURNE, Australia, Sept. 17, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed their

  47. Ionis Pharmaceuticals to present at upcoming investor conferences

    CARLSBAD, Calif., Aug. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor

  48. Ionis licenses hepatitis B program to GSK

    CARLSBAD, Calif., Aug. 27, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), the leader in RNA-targeted therapeutics, announced today that GSK exercised its option to license Ionis' antisense medicines